New treatments which can slow the progress of Alzheimer’s were given UK licences in 2024 but have not been recommended for NHS use by the cost-effectiveness assessment body NICE, a decision which will affect 70,000 patients in England.
The treatments were shown in trials to slow the rate of decline as a result of the early stages of Alzheimer’s by an average of about four to seven months.
You can read more about the decision not to recommend these medicines here.
The US, Australia, Japan, Singapore, Taiwan, South Korea, China and several nations in the Middle East and South America have provided regulatory approval for one or both of these medicines.
